Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Ontology Browser

Term:
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor (CHEBI:50568)
Annotations: Rat: (78) Mouse: (79) Human: (79) Chinchilla: (0) Bonobo: (0) Dog: (1) Squirrel: (0) Pig: (0)
Parent Terms Term With Siblings Child Terms
(2R,3S)-EHNA 
(2R,3S)-EHNA hydrochloride 
3-methylflavone-8-carboxylic acid +  
adenosine phosphodiesterase inhibitor +   
amrinone  
avanafil 
caffeine +   
DPCPX  
dyphylline +  
EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor +   
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor +   
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor +   
An EC 3.1.4.* (phosphoric diester hydrolase) inhibitor which interferes with the action of 3',5'-cyclic-nucleotide phosphodiesterase (EC 3.1.4.17).
EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor +   
EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor +   
EHNA +  
N-ethyl-5'-carboxamidoadenosine  
pimobendan  
rolipram +   
sulmazole 
theophylline +   
vardenafil 
zardaverine  

Synonyms
Related Synonyms: 3',5'-cyclic nucleoside monophosphate phosphodiesterase inhibitor ;   3',5'-cyclic nucleoside monophosphate phosphodiesterase inhibitors ;   3',5'-cyclic-nucleotide 5'-nucleotidohydrolase inhibitor ;   3',5'-cyclonucleotide phosphodiesterase inhibitor ;   3',5'-cyclonucleotide phosphodiesterase inhibitors ;   3',5'-nucleotide phosphodiesterase inhibitor ;   3',5'-nucleotide phosphodiesterase inhibitors ;   3': 5'-monophosphate phosphodiesterase (cyclic CMP) inhibitor ;   3': 5'-monophosphate phosphodiesterase (cyclic CMP) inhibitors ;   3':5'-cyclic nucleotide 5'-nucleotidohydrolase inhibitors ;   EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitors ;   EC 3.1.4.17 inhibitor ;   EC 3.1.4.17 inhibitors ;   PDE inhibitor ;   PDE inhibitors ;   cyclic 3',5'-mononucleotide phosphodiesterase inhibitor ;   cyclic 3',5'-mononucleotide phosphodiesterase inhibitors ;   cyclic 3',5'-nucleotide phosphodiesterase inhibitor ;   cyclic 3',5'-nucleotide phosphodiesterase inhibitors ;   cyclic 3',5'-phosphodiesterase inhibitor ;   cyclic 3',5'-phosphodiesterase inhibitors ;   cyclic 3',5-nucleotide monophosphate phosphodiesterase inhibitor ;   cyclic 3',5-nucleotide monophosphate phosphodiesterase inhibitors ;   cyclic AMP phosphodiesterase inhibitor ;   cyclic AMP phosphodiesterase inhibitors ;   cyclic nucleotide phosphodiesterase inhibitor ;   cyclic nucleotide phosphodiesterase inhibitors ;   cytidine 3':5'-monophosphate phosphodiesterase (cyclic CMP) inhibitor ;   cytidine 3':5'-monophosphate phosphodiesterase (cyclic CMP) inhibitors ;   nucleoside 3',5'-cyclic phosphate diesterase inhibitor ;   nucleoside 3',5'-cyclic phosphate diesterase inhibitors ;   nucleoside-3',5-monophosphate phosphodiesterase inhibitor ;   nucleoside-3',5-monophosphate phosphodiesterase inhibitors ;   phosphodiesterase III inhibitor

paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.